Puma Biotechnology's Neratinib attempts to break new ground in HER2-positive Breast Cancer market - Clinical Trials Arena
Marcus Morreale | LinkedIn
Puma Biotechnology
Neratinib Chapter
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotech punts near $300 million on Takeda discard
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Surges, Defying Yellen
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
pbyi-10k_20171231.htm
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) -November 22, 2023 at 04:30 am EST | MarketScreener
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC | Nasdaq
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
